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DObjectives: To evaluate right-sided endocarditis and compare the incidence, clinical presentations, and out-
comes in patients with a surgical and percutaneous pulmonary valve.
Methods: All patients with infective endocarditis occurring between January 2009 and June 2013 were identi-
fied and studied. All consecutive patients who received a pulmonary valve surgically or by percutaneous pulmo-
nary valve implantation (PPVI) during the same period were also evaluated for endocarditis.
Results: During the study period, 31 patients were identified with right-sided endocarditis: 13 had valves im-
planted during the study period and 18 before. The person-time incidence rates of endocarditis were 1.2 and
3.9 cases/100 person-years in the surgical and PPVI groups, respectively (P ¼ .03). Clinical presentations,
microbiology, and outcomes were comparable in both groups. The implantation-endocarditis time interval
was much shorter in the patients in the PPVI group (P ¼ .0065). A past history of endocarditis was found to
correlate with endocarditis (P¼ .004). Infective endocarditis was more frequent in patients with bovine jugular
vein valves compared with others (7.1% vs 0.84%, P ¼ .0117; odds ratio, 9). Probability of survival at 12, 24,
and 36 months was 99.5%, 93.8%, 93.8% in the surgical group and 98.9%, 96.8%, 92.3% in the PPVI group,
respectively (P ¼ .6). Event-free probability including endocarditis was comparable (P ¼ .1).
Conclusions: There is a higher incidence of endocarditis in patients with PPVI compared with surgical pulmo-
nary valves. Clinical and biological features were comparable in both groups. The role of bovine jugular veins in
the development of endocarditis is concerning. However, despite a higher incidence of endocarditis in the PPVI
group, the probabilities of survival and event-free survival were similar to the surgical group. (J Thorac Cardi-
ovasc Surg 2014;148:2253-9)See related commentary on pages 2259-60.Infective endocarditis (IE) is a life-threatening medical con-
dition that requires immediate attention. Despite significant
improvements in the diagnosis and management of IE, mor-
tality remains high. In the congenital heart disease (CHD)
population, IE is a concern in patients with prosthetic
valves. The diagnosis is usually challenging and delayed,
the need for surgery is more frequent, and the prognosis is
worse compared with IE in patients with a native valve.1-3
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The Journal of Thoracic and Carmajor complications. Overall mortality of CHD-associated
IE decreased to 10% in 1990 in comparison with 30% in
adults with IE and structural heart disease.4,5 Mortality
from surgery for IE is up to 15%; mortality after 1 year I
40% to 50%.5,6
There is a paucity of data on the incidence, clinical
presentation, treatment, and outcomes of selective
right-sided endocarditis in patients with CHD with surgi-
cal or transcatheter pulmonary valve implantation.7-10
Percutaneous pulmonary valve implantation (PPVI)
is now recognized as the treatment of choice for
dysfunctional right ventricular outflow tracts (RVOT).11
After more than a decade, its usefulness has been recog-
nized; it offers a good alternative to surgery for patients
with hemodynamically significant RVOT diseases.12
However, there are increasing reports of endocarditis
with the most frequently used valve stent (ie, the Melody
valve [Medtronic, Minneapolis, Minn]).13-16 To date,
there are no data comparing surgical and transcatheter
endocarditis. We reviewed all cases of right-sided endo-
carditis in patients who underwent surgical and trans-
catheter treatment at our center during the same period
to study the demographics, clinical presentation, micro-
biology, treatment, and outcomes.diovascular Surgery c Volume 148, Number 5 2253
Abbreviations and Acronyms
CHD ¼ congenital heart disease
CI ¼ confidence interval
IE ¼ infective endocarditis
PPVI ¼ percutaneous pulmonary valve
implantation
PVR ¼ pulmonary valve replacement
RVOT ¼ right ventricular outflow tract
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DMATERIALS AND METHODS
Data were collected from our institutional review board–approved data-
base. All patients with IE occurring between January 2009 and June 2013
were identified and studied. Diagnosis was made using the modified Duke
criteria (Table 1). All patients who received a pulmonary valve surgically
(PVR) or percutaneously during the study period at our institution were
also identified and included in the study.
Data were collected retrospectively for the surgical group and
prospectively for the transcatheter patients (this population was part of a
large prospective clinical trial). Patients receiving a valve in any other
position either percutaneously or surgically were excluded from the study.
Patients followed up abroad were also excluded from the study.
A detailed review of the medical history of all patients was undertaken,
including demographic characteristics, number of surgeries, number of
cardiac catheterizations, type of conduit, history of endocarditis and comor-
bidities (any associated chronic medical condition, syndrome, genetic abnor-
malities, chronic infection).All hadadetailed echocardiogrambefore, during,
and after implantation. Follow-up outcomes were recorded. Patients were
diagnosed as having IE based on the modified Duke criteria. Clinical presen-
tation, bacteriologic diagnosis, evolution, and treatment were recorded.
Prevention of endocarditis in the PPVI group evolved over time. When
we started the PPVI program, the patients were free of infection at the time
of implantation and received antibioprophylaxis at the time of the proce-
dure. Since mid-2011, the same protocol has been used for all patients
receiving a valve, either surgically or percutaneously. Before the valve pro-
cedure, all patients undergo dental clearance. Cefamandole is given in the
operating room or in the catheterization laboratory at the start of the proce-
dure and is continued for 24 hours.Statistical Analysis
Analyses were performed using MedCalc software (Mariakerke,
Belgium). A comparison between the surgical and transcatheter PPVI
groups was performed for endocarditis. Endocarditis occurring on conduits
placed before the study began were excluded from the calculation of the
incidence of IE.
The person-time incidence rate with the 95% confidence interval (CI)
for a Poisson distribution was calculated for the PPVI group and the surgi-
cal group. The probability of survival and the probability of cardiovascular
event/endocarditis–free survival were calculated for each group using the
Kaplan-Meyer method. Survival probability included death and heart trans-
plantation; cardiovascular events included IE, surgery for IE, or death. Data
are presented as the mean value  SD when variables were normally
distributed, and the median value with 95% CI when it was not. The
PPVI and surgical groups were compared using theWilcoxon test for quan-
titative variables and the c2 test or Fisher test for qualitative variables. The
relationship between risk factors for IE (sex, age, type of CHD, age at PVR,
pulmonary arterial stenting and the number of procedures, history of infec-
tious history, history of IE and comorbidities, type of prosthetic material for
pulmonary valve) and IE was assessed using Cox proportional hazard
regression analysis. Only factors significantly associated with IE with
P<.05 where used in the multivariate model.2254 The Journal of Thoracic and Cardiovascular SurRESULTS
Endocarditis Occurring Between January 2009 and
June 2013
During the study period, 31 patients were identified with
right-sided endocarditis: 13 had valves implanted during the
study period and 18 had right ventricle to pulmonary artery
conduits implanted before 2009. Twenty-three patients
had a surgical conduit and 8 patients had Melody valve
implantation (Table 2). In the surgical group, 3 had
homografts, 3 had a nonvalve conduit, and 17 had a
bioprosthesis (14 Contegra [Medtronic], 1 Hemashield
[St Jude Medical, St Paul, Minn], 1 Magma [Edward
Lifesciences, Irvine, Calif], and 1 Hancock [Medtronic]).
When we compared surgical IE and PPVI IE, gender and
the number of previous surgeries were similar (Table 2).
The implantation-IE time interval was different in the 2
groups; IE occurred much earlier in the PPVI group
compared with the surgical group (P ¼ .0065). Only 5 of
23 occurrences of IE during the study period had
RVOT conduits implanted during the study period; all
others had RVOT conduits implanted before January
2009. In addition, early onset of IE (defined as endocarditis
within 1 year of implantation) was more frequent in the
PPVI group and this tended to reach statistical significance
(P ¼ .052).
The severity of the clinical presentation at diagnosis was
not different in the 2 groups. In the surgical group, severe
presentation was always associated with Staphylococcus
aureus infection. Gradients across the RVOT increased
globally in both groups during IE and were similar before
and during IE. In the surgical group, vegetation was seen
in the RVOT in 18 patients. In the PPVI group with IE,
vegetation was identified in the RVOT in 6 of 8 cases.
The size of the vegetation was not reported but the increase
in the RVOT gradient in most of these patients in both
groups indicates that the vegetation was significant. The
need for surgery to remove the infected material was not
different in for surgical and transcatheter IE (Table 2).
The microbiological diagnosis for IE was also similar in
both groups (Table 3).
Overall mortality (related or unrelated to IE) at last
follow-up was 19%: 37% in the PPVI group and 13%
in the surgical group (P ¼ NS). In the surgical group
with IE (n ¼ 23), 2 patients had surgery to remove the in-
fected conduit, 2 were treated medically (1 died 5.5
months after the onset of IE of febrile shock) and 1 had
early heart transplantation for intractable endocarditis. In
the PPVI group with IE (n ¼ 8), 2 died acutely of severe
cardiogenic shock; another had balloon dilation of the
RVOT and died 6 months after onset of IE. Death was
caused by biventricular heart failure and not IE. One pa-
tient needed emergency balloon dilation of the RVOT fol-
lowed by surgery, 1 patient needed surgery, and 3 patients
were treated medically.gery c November 2014
TABLE 1. Modified Duke criteria
Diagnosis of IE is definite in the presence of 2 major criteria or 1 major and 3 minor criteria or 5 minor criteria
Diagnosis of IE is possible in the presence of 1 major criteria and 1 minor criteria or 3 minor criteria
Major criteria Minor criteria
Blood cultures positive for IE:
— Typical microorganisms consistent with IE from 2 separate blood
cultures (Viridans streptoccoci, Streptococcus bovis, HACEK group,
Staphylococcus aureus; or community-acquired enterococci, in the
absence of a primary focus)
— or microorganisms consistent with IE from persistently positive blood
cultures: at least 2 positive blood cultures drawn>12 h apart; or all 3
or a majority of>4 separate blood cultures
— or a single positive blood culture for Coxiella burnetii or phase I IgG
antibody titer>1:800
Predisposition: heart condition, intravenous drug use
Fever (>38C)
Vascular phenomena: major arterial emboli, septic pulmonary infarcts,
mycotic aneurysm, intracranial hemorrhages, conjunctival hemorrhages,
Janevay lesions
Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots,
rheumatoid factor
Microbiological evidence: positive blood culture but does not meet major
criteria for or serologic evidence of active infection with organism
consistent with IE
Evidence of endocardial involvement:
— echocardiography positive for IE (vegetation, abscess, dehiscence of
prosthetic valve)
— new valvular regurgitation
IE, Infective endocarditis; HACEK, Haemophilus, Aggregatibacter (previously Actinobacillus), Cardiobacterium, Eikenella corrodens, Kingella; IgG, immunoglobulin G.
Adapted from Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin
Infect Dis. 2000;30:633-8.
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Between January 2009 and June 2013, 93 patients
received 93 Melody valves and 195 right ventricle to pul-
monary artery conduits were implanted in 190 patients in
our institution. Demographics, types of conduit, and rea-
sons for implantation are summarized in Table 4. The period
of follow-up was similar for the surgical and PPVI groups
with a median of 24.1 months (95% CI, 19.9-29.9 months)
and 23.8 months (95% CI, 17.5-32.5 months), respectively.
Patients in the surgical group were younger than patients
receiving a Melody valve (median, 13.3 years vs 20.1 years,
P< .01). Patients undergoing Melody valve implantation
had a higher number of previous surgeries than the surgical
patients (P<.001). Amongst the 288 RVOT interventions,
13 patients developed right-sided endocarditis: 5 of 190 sur-
gical patients (incidence, 2.6%  2.2%; 95% CI, 0.35%-
4.8%) and 8 of 93 PPVI patients (incidence, 8.6% 
5.7%; 95% CI, 2.9%-14.3%). Person-time incidence rates
of IE were 2.4, 1.2, and 3.9 cases per 100 person-years for
the total population, the surgical group, and the PPVI group,
respectively (surgical vs PPVI, P¼ .03). The probability of
being free of IE in the PPVI group was significantly lower
compared with the surgical group (P ¼ .029; Figure 1).Risk Factors
In the surgical group, 3 of 5 patients had a previous
history of IE. In the PPVI group, 1 patient had a previous
history of IE. These patients had different causative germs
except for 1 patient in the surgical group who had early
recurrence of IE with Staphylococcus aureus (Table 5). Us-
ing univariate analysis, IE was 7 times more likely to occur
when the patient had a history of IE in the surgical group
(relative risk, 7.3; 95% CI, 2.2-23.6; P ¼ .001) and 3 timesThe Journal of Thoracic and Carmore likely in the PPVI group (relative risk, 3.31; 95% CI,
1.1-10.1; P ¼ .03). There was no association between the
occurrence of IE and age at time of the procedure, gender,
history of noncardiac bacterial infection, presence of co-
morbidities, number of surgeries, and the presence of stents
in the pulmonary arteries. In multivariate analysis, only a
history of IE was associated with IE (P ¼ .004). When
we compared the person-years incidence rate of IE with
and without a history of IE, the difference was significant
in the surgical group (19.7% with history of IE and 0.5%
without a history of IE, P< .0001) but not in the PPVI
group (P ¼ .7). Moreover, when analyzing the type of
valves regardless of the implantation technique, IE was
more frequent in patients with bovine jugular vein
valves (ie, Contegra and Melody) compared with
others (12/169 ¼ 7.1% [4%-12%] vs 1/119 ¼ 0.84%
[0%-5%], P ¼ .0117; OR ¼ 9 [1.16-70.33]).Outcome in Patients Who Had Surgical and PPVI
Procedures
In this series of patients, 11 surgical patients died as a
result of cardiac events including 2 in the context of IE.
Four PPVI patients died: 3 patients described earlier and
1 patient (who did not have IE) with biventricular failure
(end-stage ventricular failure). The all-cause mortality
rate (including endocarditis) was not different between
the 2 groups (surgical group, 5.61%; PPVI group, 4.30%;
P¼ .6). The probability of survival at 12, 24, and 36 months
was 99.5%, 93.8%, and 93.8% in the surgical group and
98.9%, 96.8%, and 92.3% in the PPVI group, respectively
(P¼ .6; Figure 2). The probability of cardiovascular event–
free survival including IE was not different between the 2
groups (P ¼ .1; Figure 3).diovascular Surgery c Volume 148, Number 5 2255
TABLE 3. Patients with IE: comparison between surgical IE and
PPVI (Melody valve) IE
Surgery
(n ¼ 23) PPVI (n ¼ 8) P value
Age, y (median) [95% CI] 15.9 [10.5-21.9] 27.5 [13.5-47.9] .06
Male/female 16/7 7/1 NS
Type of defect, n
DORV-PS 6 2
Truncus arteriosus 1 1
PA-VSD 6 1
TOF 7 2
Aortic stenosis 2 2
Complex 1 —
Number of surgeries,
mean  SD
2.5  1.3 2.6  0.7 NS
Conduit, n —
HG 3 2
Contegra 14 0
Bioprosthesis 3 5
Nonvalve conduit 1 0
Patched 2 1
Comorbidities 9 3 —
History of infection 7 1 —
History of IE 4 1 —
Age of the conduit or last
surgery, y (mean)
[95% CI]
9.2 [2.7-11.9] 11.2 [2.3-16.3] NS
Age of Melody valve or the
conduit, y (mean)
[95% CI]
9.2 [2.7-11.9] 0.95 [0.29-3.2] .0065
Last echo gradient
<2 m/s 5 0 NS
2-4 m/s 14 7
>4 m/s 4 1
Clinical presentation
Severe (sepsis, heart
failure)
4 4 NS
Fever, malaise 19 4
Early onset after surgery
or after PPVI, n (%)
3 (13.04) 4 (50) .05
Echo gradient during IE
<2 m/s 2 0 NS
2-4 m/s 11 5
>4 m/s 10 3
Vegetation, n 18 6 —
Shock on admission, n (%) 4 (17.4) 3 (37.5) NS
Need for surgery because
of IE, n (%)
13 (56.5) 4 (50) NS
Outcome
Alive 20 5 NS
Death 3 (1 TLX) 3
Early death 2 (1 TLX) 2
Late death 1 1
IE, Infective endocarditis; PPVI, percutaneous pulmonary valve implantation; CI,
confidence interval; NS, not significant; DORV-PS, double-outlet right ventricle
with pulmonary stenosis; PA-VSD, pulmonary atresia-ventricular septal defect;
TOF, tetralogy of Fallot; SD, standard deviation; HG, homograft; TLX, heart trans-
plantation.
TABLE 2. Characteristics of the surgical population and the PPVI
(Melody valve) population
Surgery
(N ¼ 195) PPVI (N ¼ 93) P value
Age at PVR, y (median)
[95% CI]
13.3 [11.6-15.0] 20.1 [18.2-21.8] <.01
Male/female 111/79 52/41 —
Type of defect —
TOF 69 24
PA-VSD 37 23
Truncus arteriosus 12 11
Aortic disease 31 13
DORV-PS 9 3
Complex 32 19
Number of surgeries, mean
[95% CI]
1 [1-2] 2 [2-3] <.001
Type of conduit —
Homograft 65 (33%) 19 (20%)
Bioprosthesis* 37 (19%) 40 (43%)
Contegra 76 (39%) 12 (13%)
Nonvalve Gore-Texy conduit 17 (9%) 5 (6%)
Patched RVOT — 17 (18%)
History of endocarditis 11 6 NS
Comorbidities 36 22 NS
Outcome —
IE 5 8
Death 11 4
Heart transplantation 1 0
PPVI, Percutaneous pulmonary valve implantation; PVR, pulmonary valve replace-
ment; CI, confidence interval; TOF, tetralogy of Fallot; PA-VSD, pulmonary
atresia-ventricular septal defect; DORV-PS, double-outlet right ventricle with pulmo-
nary stenosis; RVOT, right ventricular outflow tract; NS, not significant; IE, infective
endocarditis. *Bioprosthesis: Vascutek (Terumo, Inchinnan, Scotland), Carbomedics
(Sorin, Clamart, France), Freestyle (Medtronic, Minneapolis, Minn), Carpentier-
Edwards (Edwards Lifesciences, Irvine, Calif), Hancock (Medtronic), Perimount
(Edwards Lifesciences), Magna (Edwards Lifesciences), Hemashield (St Jude Med-
ical, St Paul, Minn), Labcor (Labcor Laboratorios, Belo Horizonte, Brazil), Shelhigh
(Shelhigh Inc, Millburn, NJ), St Jude aortic (St Jude Medical). yGore-Tex; W.L. Gore
and Associates, Flagstaff, Ariz.
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DDISCUSSION
Despite a sizable number of interventions and surgeries
on RVOT, there are limited data on the incidence, clinical
presentation, treatment, and outcomes of right-sided
endocarditis in patients with CHD with prosthetic material
implanted at the RVOT.7-16 We reviewed all cases of
right-sided endocarditis in patients treated at our centre
during the study period. Patients were diagnosed with IE
based on the modified Duke criteria (Table 1).
Various valves and conduits have been in use during the
study period. The incidence of IE based on the pulmonary
valve prosthetic material showed significant variation. We
did not find a difference in the incidence of IE between con-
duits but the number of patients was probably too small for
statistical analysis. Moreover, Albanesi and colleagues8
recently reported the long-term results on the Contegra
valve and described an incidence of IE as high as 11.3%.2256 The Journal of Thoracic and Cardiovascular Surgery c November 2014
TABLE 4. Microorganisms found in endocarditis
Bacteria PPVI (n ¼ 8) Surgery (n ¼ 23)
Streptococcus 4 9
Staphylococcus epidermidis 2 4
Methicillin-sensitive
Staphylococcus aureus
1 3
Bartonnella — 1
Kingella kingae — 1
Enterobacter faecium — 1
Enterococcus faecalis — 1
Pseudomonas aeruginosa — 2
Propionibacterium acnes 1 —
Negative blood culture — 1
PPVI, Percutaneous pulmonary valve implantation.
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was within the same range as that for the Contegra. This
peculiar finding raises questions on the nature of the pros-
thetic material and susceptibility to IE; the Contegra and
Melody valves have the same biological origin (ie, bovine
jugular vein). Following this common origin, we analyzed
the risk of endocarditis in all implanted conduits regardless
of implantation technique and found a close association be-
tween bovine jugular vein and IE. There are as yet no clear
explanations for this. Various interesting hypotheses may be
postulated, such as higher tropism for bacteria, higher
thrombogenicity, biologically active surface working like
a sink in contrast to other inert conduits or homografts,
lower rate of endothelialization, and so forth.
The findings put bovine jugular vein material as a poten-
tially important substrate for such high susceptibility to
endocarditis. However, the relatively high incidence of IE
with the Melody and Contegra valves is probably more
multifactorial resulting from complex interactions of sub-
strates and triggers: intrinsic susceptibility of the conduit
for IE, residual turbulence in the RVOT, unmodifiable
anatomic factors, and abrupt cessation of antiaggregrant
therapy with thrombi filling up the valve cusps.FIGURE 1. Freedom from infective endocarditis in the surgical group and
the percutaneous pulmonary valve implantation (Melody valve) group. IE,
Infective endocarditis; PPVI, percutaneous pulmonary valve implantation.
The Journal of Thoracic and CarOne of the answers to the potential role of the type of
conduit in the development of IE may be elucidated by
the ongoing studies of the SAPIEN valve inserted in the
pulmonary position.17 However, preliminary results on
pericardial valves in the aortic position showed an incidence
of IE of 3.4% at 1 year and this is similar to what we
describe here.18 Long-term studies focusing on right-sided
lesions are still awaited before drawing final conclusions.
When comparing surgical RVOT IE and transcatheter
RVOT IE, there was no difference in the clinical presenta-
tion. The microbiological diagnosis, treatment, and out-
comes were similar in both groups, confirming that
prosthetic valve IE is a serious complication requiring ur-
gent medical treatment and surgery to remove the infected
material in most cases. Global mortality remains high
regardless of the type of reconstructed RVOT and despite
aggressive treatment. The main difference in the 2 groups
was the time between implantation and onset of IE, which
was noted to be much earlier after valve implantation in
the PPVI group. However, this does not imply that Melody
valve IE always has an early presentation because some of
the patients presented with IE 4 years after PPVI. On multi-
variate analysis, a past history of IE was the only risk factor
identified. This finding raises the question of whether pa-
tients with a past history of IE are good candidates for
PPVI. There is no clear answer to that question because
the risk was only statistically significant for the surgical
population and not for the PPVI patients. We still consider
these patients as candidates for PPVI if the patient is free of
endocarditis 1 year after previous endocarditis. Larger
studies are necessary before giving a conclusive answer.
Despite a higher incidence of endocarditis in the Melody
PPVI group compared with surgery, it cannot be concluded
that the use of this devicemay be harmful. The overall results
should be put into perspective and the impact of different
techniques in the 2 groups may be playing some role. There
seems to be some trade off because although patients with
PPVI have a higher risk for endocarditis, it is also possible
that they may have less invasive, perioperative or other car-
diovascular events and complications. In our study, survival
curves and freedom from cardiovascular events including
IE were similar in the surgical and the PPVI groups despite
a higher rate of endocarditis in the PPVI group.
In addition to the different techniques and substrates
used, it could be advocated that sterile techniques are
more stringent in the operating room than in the catheteriza-
tion laboratory. This is undoubtedly true but early onset
of IE in the PPVI group is not the only mode of
presentation and, more importantly, bacteria causing IE
are usually issued from the ear, nose, and throat or are
methicillin-sensitive Staphylococcus, making procedural
contamination less likely to be the cause.
Patients should be made aware of the possible complica-
tions. Strict measures should be taken to limit the risk ofdiovascular Surgery c Volume 148, Number 5 2257
TABLE 5. Microorganisms in patients with a history of infective endocarditis
Patient number Group
Interval between first and
second IE Microorganism at first IE Microorganism at second IE
1 Surgery 15 d Staphylococcus aureus Same bacteria
2 Surgery 3 mo Enterococcus Staphylococcus epidermidis
3 Surgery 14 mo Staphylococcus epidermidis Kingella kingae
4 Surgery 4 y Negative blood culture Streptococcus sanguis
5 PPVI 23 mo Streptococcus gordonii Streptococcus gallolyticus
IE, Infective endocarditis; PPVI, percutaneous pulmonary valve implantation.
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Dendocarditis with antibioprophylaxis, strict asepsis, and so
forth.19 Patients undergoing PPVI should be considered as
patients undergoing surgery and should have the same pre-
liminary testing (dental care, otorhinolaryngology, and so
forth). Physicians should be aware of this complication
and should refer the patient to a tertiary hospital with any
suspicion of endocarditis for prompt diagnosis and manage-
ment. Our management strategy after the onset of IE was
based on the European Society for Cardiology guidelines,5
Antimicrobial therapy was given for 6 weeks. Indications
for surgery were heart failure (secondary to increased right
ventricular outflow tract obstruction), uncontrolled sepsis
with septic shock, or persistent infection in the urgent cases.
In semielective or elective surgery for IE, the reason for
intervention was right ventricular outflow tract obstruction
or relapse of IE despite adequate antibiotic treatment.
Limitations
Given the retrospective nature of the data collection in the
surgical group, it is possible that anecdotal episodes of IE
may not have been reported in our database. The incidence
of IE may thus have been underestimated in the surgical
group. However, to reduce this bias, each patient and the
doctors following the patients were contacted by phone. Pa-
tients from abroad were excluded from this study. All pa-
tients in the Melody valve group were followed strictly
according to protocol in our institution with accurateFIGURE 2. Survival curve in the surgical group and the percutaneous pul-
monary valve implantation (Melody valve) group. PPVI, Percutaneous pul-
monary valve implantation.
2258 The Journal of Thoracic and Cardiovascular Surdiagnosis and reporting of IE. This is a descriptive study
and the number of events is low making the statistics less
robust. We were unable to accurately determine the inci-
dence of IE based on the bioprosthetic conduit material in
more detail because multiple conduits were used over the
years. Thus, the global incidence was assessed.
CONCLUSIONS
RVOT IE in patients with CHD is a serious compli-
cation requiring aggressive medical and surgical treat-
ment in most cases. There is a high person-time
incidence of endocarditis in patients with the Melody
valve compared with surgically implanted pulmonary
valves. This is probably multifactorial. Intrinsic charac-
teristics of the bovine jugular vein may play a major
role in IE as we found an increased risk of endocarditis
in patients receiving a bovine jugular vein valve either
surgically or by the transcatheter technique. It is
possible that there is enhanced tropism of microbes to
the bovine jugular vein, however, in vitro studies may
be required to establish this hypothesis. Clinical presen-
tation and a microbiological diagnosis of IE were
comparable in the surgical and PPVI patients. A past
history of IE remains a major risk factor for the
development of future IE in both groups. Multicenter
studies are needed to pool a larger number of patients
and identify strong predictors for IE in this population.FIGURE 3. Freedom from cardiovascular events in the surgical group and
the percutaneous pulmonary valve implantation (Melody valve) group.
PPVI, Percutaneous pulmonary valve implantation.
gery c November 2014
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heart valves may answer questions on whether the
percutaneous approach is a possible risk factor along
with other substrates based on prosthetic material.
Despite a higher incidence of endocarditis with the
Melody valve, probabilities of survival and event-free
survival were similar to the surgical group.
The authors thank Dr Mehul Patel for editing the paper.
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Dis. 2012;105:454-60.MMENTARYEndocarditis and the transcatheter pulmonary valveRichard A. Jonas, MDThe article in this issue of the Journal by Malekzadeh-
Milani and colleagues1 from the pediatric cardiology
department at the renowned Necker Hospital in Paris re-
ports a disturbingly high risk for endocarditis in the Melody
valve (Medtronic Inc, Minneapolis, Minn) relative to surgi-
cally implanted conduits. Surgically implanted conduits
containing a bovine jugular valve (Contegra conduits; Med-
tronic Inc) also appear to have a higher risk of endocarditis
relative to other surgical options.
This is an important article. There have been an
increasing number of anecdotal reports in the literature sug-
gesting that the Melody valve might have a higher risk for
endocarditis than surgically implanted pulmonary valves.
A multi-institutional report in 2013 described an importantdiovascular Surgery c Volume 148, Number 5 2259
